Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maribavir prophylaxis for prevention of cytomegalovirus disease after allogeneic stem cell transplantation
2006-005692-18Phase 3Completed
- Sponsor
- ViroPharma Incorporated
- Start
- Feb 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cytomegalovirus disease (CMV) comparing Maribavir prophylaxis with Placebo (2 arms). Primary endpoints: Incidence of CMV disease within 180 days post-transplant, Incidence of CMV disease within 100 days post-transplant and 1 more. Started Feb 2007; status: completed.
02
Drugs
maribavir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2006-005692-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005692-18.